| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Santos David A | EVP, Chief Commercial Officer | RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO | /s/ Raymond Furey (Attorney-in-Fact) | 04 Feb 2026 | 0001820066 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RIGL | Common Stock | Tax liability | $205,905 | -5,718 | -11% | $36.01 | 46,986 | 02 Feb 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Includes 1,000 shares acquired under the Issuer's stock purchase plan. |